Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C

被引:91
|
作者
Caballero, T
Pérez-Milena, A
Masseroli, M
O'Valle, F
Salmerón, FJ
Del Moral, RMG
Sánchez-Salgado, G
机构
[1] Univ Granada, Sch Med, Dept Pathol, Granada 18012, Spain
[2] Univ Granada, Univ Hosp, Granada 18012, Spain
[3] Univ Granada, Sch Med, Dept Internal Med, Granada 18012, Spain
关键词
hepatitis C; liver fibrosis; image analysis; automatic quantification; Knodell activity index; Scheuer activity grade; Knodell fibrosis scoring; Scheuer fibrosis staging; interferon;
D O I
10.1016/S0168-8278(01)00006-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The effect of interferon on the reduction of liver fibrosis is controversial. We aimed to compare semiquantitative methods with a quantitative digital image analysis system to assess liver fibrosis in biopsies from patients with chronic hepatitis and different responses to interferon, Methods: We studied 98 liver biopsies with chronic hepatitis C before and after recombinant interferon alfa-2 treatment, using conventional histological assessment, grading of histological activity, scoring/staging of fibrosis (Knodell and Scheuer), and quantification of fibrosis with image analysis (FibroQuant). Results: Sustained-responders to interferon showed a significant reduction in histological lesions and in their Knodell and Scheuer activity indexes. The semiquantitative systems showed no reduction in fibrosis, The FibroQuant application showed a significant reduction in porto-periportal and septal areas among sustained-responders (P < 0.001) and non-responders (P < 0.05), and in porto-periportal and septal fibrosis areas only in sustained-responders (P < 0.001), whereas the percentage of fibrosis increased in non-responders (P < 0.001). Conclusions: The Scheuer system is useful for the daily evaluation of fibrosis, but the FibroQuant application provides more objective data on the anti-fibrogenic effects of interferon, which include a reduction in the portoperiportal area in sustained-responders and non-responders, accompanied by a reduction in the area of fibrosis only when the viral replication has ceased. (C) 2001 European Association for the Study of the Liver. Published by Elsevier Science B,V, All rights reserved.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [31] Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients
    Thelu, MA
    Baud, M
    Leroy, V
    Seigneurin, JM
    Zarski, JP
    JOURNAL OF CLINICAL VIROLOGY, 2001, 22 (01) : 125 - 131
  • [32] Retreatment of IFN/ribavirin non-responder hepatitis C patients: Benefit of PEG-interferon/ribavirin amantadine.
    Maynard, M
    Ahmed, SNS
    Bailly, F
    Rozier, F
    Benmakhlouf, N
    Bourne-Branchu, V
    Fazly, T
    Nemoz, C
    Adeleine, P
    Pradat, P
    Trepo, C
    HEPATOLOGY, 2004, 40 (04) : 398A - 398A
  • [33] Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen
    Biselli, M
    Andreone, P
    Gramenzi, A
    Lorenzini, S
    Loggi, E
    Bonvicini, F
    Cursaro, C
    Bernardi, M
    DIGESTIVE AND LIVER DISEASE, 2006, 38 (01) : 27 - 32
  • [34] Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study
    Andreone, P
    Cursaro, C
    Gramenzi, A
    Fiorino, S
    Di Ciammarino, L
    Miniero, R
    D'Errico, A
    Grigioni, WF
    Gasbarrini, G
    Bernardi, M
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (08): : 688 - 694
  • [35] Low dose ribavirin (RBV) in combination interferon (IFN) for the treatment of hepatitis C non-responder and relapse patients.
    Bernstein, DE
    Khan, R
    Jeffers, LJ
    Reddy, KR
    Schiff, ER
    HEPATOLOGY, 1998, 28 (04) : 702A - 702A
  • [36] CHANGES IN ELF SCORE DURING TREATMENT WITH PEGYLATED INTERFERON AND SILYMARIN ARE ASSOCIATED WITH PROGRESSION OF HISTOLOGICAL LIVER DISEASE IN NON-RESPONDER PATIENTS WITH HEPATITIS C
    Tanwar, S.
    Ellis, E.
    Parkes, J.
    Herold, C.
    Rosenberg, W.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S55 - S55
  • [37] Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients
    Sagnelli, Caterina
    Uberti-Foppa, Caterina
    Galli, Laura
    Pasquale, Giuseppe
    Coppola, Nicola
    Albarello, Luca
    Doglioni, Carlo
    Lazzarin, Adriano
    Sagnelli, Evangelista
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2014, 18 (02): : 164 - 169
  • [38] Cyclic and periodic interferon treatment repeated with interferon beta induction plus interferon alpha maintenance as a novel approach for interferon non-responder chronic hepatitis C patients with breakthrough.
    Kishida, Y
    Naitoh, M
    Katayama, K
    Itoh, M
    Egawa, S
    Kashiwagi, T
    Hayashi, N
    HEPATOLOGY, 2001, 34 (04) : 592A - 592A
  • [39] Retreatment for chronic hepatitis C of interferon non-responder patients.: Preliminary results of a multicenter randomized controlled trial of interferon plus ribavirin versus interferon alone.
    de Lédinghen, V
    Bernard, PH
    Trimoulet, P
    Bourlière, M
    Portal, I
    Rémy, AJ
    Szostak, N
    Longo, F
    Thiefin, G
    Abergel, A
    Dumas, F
    Lucidarme, D
    Blanc, P
    Zylberberg, H
    Capron, D
    Doll, J
    Fleury, H
    Couzigou, P
    HEPATOLOGY, 1998, 28 (04) : 374A - 374A
  • [40] Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients
    Manns, MP
    Berg, T
    Wedemeyer, H
    Hinrichsen, H
    Cholewinska, G
    Zeuzem, S
    Blum, H
    Buerger, V
    Klade, C
    Tauber, E
    Jelovcan, S
    Buschle, M
    Frisch, J
    HEPATOLOGY, 2004, 40 (04) : 251A - 251A